세계의 MiRNA 시퀀싱·어세이 시장 규모는 2024년에 227억 6,000만 달러로, 예측 기간에는 332억 3,000만 달러에 달할 것으로 예측되며, 2030년까지 CAGR은 6.58%입니다.
세계의 MiRNA 시퀀싱·어세이 시장은 유전체학 및 분자생물학의 최전선에 위치한 역동적이고 빠르게 발전하는 분야입니다. 마이크로RNA(miRNA)는 다양한 생물학적 과정에서 유전자 발현을 조절하는 데 매우 중요한 역할을 하는 저분자 RNA입니다. 이 시장은 최근 질병 기전 규명 및 잠재적 치료 표적 발굴에 있으며, miRNA의 중요성이 인식되면서 최근 큰 성장을 거듭하고 있습니다. 발생, 면역 및 질병과 관련된 중요한 세포 경로에 관여하므로 miRNA는 연구 및 진단 용도에서 중요한 표적이 되고 있습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모(2024년) | 227억 6,000만 달러 |
| 시장 규모(2030년) | 332억 3,000만 달러 |
| CAGR(2025-2030년) | 6.58% |
| 급성장 부문 | SBS(합성에 의한 시퀀싱) |
| 최대 시장 | 북미 |
세계의 MiRNA 시퀀싱·어세이 시장의 주요 촉진요인은 맞춤형 의료와 정밀진단에 대한 수요 증가입니다. 연구개발자와 임상의들은 miRNA 프로파일링을 활용하여 표적 치료법을 개발하고 질병을 조기에 발견할 수 있는 바이오마커를 식별하고 있습니다. 다양한 질병과 관련된 고유한 miRNA 발현 패턴을 이해함으로써 의료 전문가는 환자 개개인에 맞는 치료 전략을 수립하여 효과를 극대화하고 부작용을 최소화할 수 있습니다. 의료 분야에서 개인 맞춤형 접근법을 중시하는 추세에 따라 다양한 임상 전문 분야에서 miRNA 시퀀싱 분석 기술의 채택이 가속화되고 있습니다.
세계 miRNA 시퀀싱 분석 시장은 건강과 질병에서 miRNA의 역할에 대한 인식이 높아짐에 따라 유전체학 및 분자생물학 환경의 중요한 컴포넌트로 자리 잡고 있습니다. 맞춤형 의료에 대한 수요 증가, 기술 발전, miRNA의 생물학에 대한 이해도가 높아짐에 따라 이 시장은 지속적인 성장과 혁신이 예상됩니다. 연구자와 임상의가 miRNA 시퀀싱 분석 기술의 힘을 활용하여 질병 메커니즘에 대한 새로운 인사이트을 얻고 표적 치료법을 개발함에 따라 의료 분야의 혁신적 발전 가능성은 무궁무진합니다.
만성질환의 유병률 상승
시퀀스 기술의 진보
마이크로어레이 기반 기술
데이터 해석의 복잡성
고비용
바이오인포매틱스 툴의 통합
Global MiRNA Sequencing and Assay Market was valued at USD 22.76 Billion in 2024 and is anticipated to reach USD 33.23 Billion in the forecast period with a CAGR of 6.58% through 2030. The Global MiRNA Sequencing and Assay Market is at the forefront of genomics and molecular biology, representing a dynamic and rapidly evolving sector. MicroRNAs (miRNAs) are small RNA molecules that play a pivotal role in regulating gene expression across various biological processes. This market has experienced substantial growth in recent years, fueled by the increasing recognition of miRNAs' significance in understanding disease mechanisms and identifying potential therapeutic targets. With their involvement in crucial cellular pathways related to development, immunity, and disease, miRNAs have become key targets for research and diagnostic applications.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 22.76 Billion |
| Market Size 2030 | USD 33.23 Billion |
| CAGR 2025-2030 | 6.58% |
| Fastest Growing Segment | Sequencing by Synthesis |
| Largest Market | North America |
A primary driver of the global miRNA sequencing and assay market is the growing demand for personalized medicine and precision diagnostics. Researchers and clinicians are leveraging miRNA profiling to develop targeted therapies and identify biomarkers for early disease detection. By understanding the unique miRNA expression patterns associated with different diseases, healthcare professionals can tailor treatment strategies to individual patients, maximizing efficacy and minimizing side effects. This emphasis on personalized approaches to healthcare has propelled the adoption of miRNA sequencing and assay technologies across diverse clinical specialties.
The Global MiRNA Sequencing and Assay Market represents a vital component of the genomics and molecular biology landscape, driven by the growing recognition of miRNAs' role in health and disease. With increasing demand for personalized medicine, technological advancements, and a deeper understanding of miRNA biology, this market is poised for continued growth and innovation. As researchers and clinicians harness the power of miRNA sequencing and assay technologies to unlock new insights into disease mechanisms and develop targeted therapies, the potential for transformative advancements in healthcare is immense.
Key Market Drivers
Rising Prevalence of Chronic Diseases
The Global MiRNA Sequencing and Assay Market is witnessing a significant boost due to the rising prevalence of chronic diseases worldwide. Chronic diseases, which include conditions such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders, have become a global health concern, contributing to a substantial portion of morbidity and mortality. According to data from the World Health Organization (WHO) in 2024, non-communicable diseases (NCDs) were responsible for at least 43 million deaths in 2021, representing 75% of all non-pandemic-related deaths globally. In the same year, 18 million individuals died from NCDs before reaching the age of 70, with 82% of these premature deaths occurring in low- and middle-income countries. Cardiovascular diseases were the leading cause of NCD-related fatalities, accounting for at least 19 million deaths in 2021, followed by cancers (10 million), chronic respiratory diseases (4 million), and diabetes (over 2 million, including kidney disease deaths caused by diabetes). MiRNA sequencing and assay technologies are playing a pivotal role in addressing the challenges posed by these chronic diseases. Chronic diseases are often characterized by complex and multifactorial genetic underpinnings, making their diagnosis, prognosis, and treatment a daunting task. MiRNAs, as small regulatory RNA molecules, are intricately involved in the regulation of gene expression and have been found to play a crucial role in the development and progression of many chronic diseases. Their unique ability to modulate the expression of multiple genes simultaneously makes them attractive candidates for understanding the underlying molecular mechanisms of these conditions.
Researchers and clinicians are increasingly turning to miRNA profiling to unravel the intricate web of molecular events associated with chronic diseases. By identifying specific miRNA signatures or dysregulations, they can gain insights into disease mechanisms and develop innovative diagnostic and therapeutic strategies. MiRNA sequencing and assays provide the tools necessary to comprehensively analyze these small but influential RNA molecules. One of the most significant advantages of using miRNA sequencing and assays in the context of chronic diseases is the potential for early diagnosis and personalized treatment. MiRNA profiles can serve as biomarkers for disease risk assessment, allowing for the detection of diseases at an earlier, more manageable stage. Furthermore, by understanding the unique miRNA expression patterns in individual patients, personalized treatment plans can be developed, targeting the specific molecular pathways involved in their condition.
Advancements in Sequencing Technologies
Advancements in sequencing technologies have played a pivotal role in propelling the Global MiRNA Sequencing and Assay Market to new heights. MiRNA sequencing and assay technologies have undergone remarkable improvements, leading to increased efficiency, accuracy, and affordability, which have in turn stimulated their adoption and utilization across various research and clinical applications. The introduction of advanced next-generation sequencing (NGS) platforms, including Illumina, Pacific Biosciences, and Oxford Nanopore, has revolutionized genomics by enabling the simultaneous sequencing of millions to billions of DNA fragments. This advancement has created new opportunities for exploring genetic variation, gene expression, epigenetic changes, and microbial diversity. One of the primary drivers of this market growth is the evolution of next-generation sequencing (NGS) technologies. NGS has revolutionized the field of genomics by enabling high-throughput and massively parallel sequencing of nucleic acids, including miRNAs. These platforms have become more cost-effective and accessible, allowing researchers to profile miRNAs with unprecedented precision. The ability to simultaneously analyze multiple miRNAs in a single experiment, along with the rapid turnaround time, has made NGS a go-to technology for miRNA research.
In addition to NGS, microarray-based techniques have also advanced, further diversifying the tools available for miRNA profiling. Microarrays provide a complementary approach to miRNA analysis, allowing researchers to simultaneously examine the expression levels of numerous miRNAs on a single chip. The development of highly sensitive and specific microarray platforms has extended the reach of miRNA sequencing and assays, offering options that cater to different research needs and budgets. Advancements in sequencing technologies have also led to improved data analysis pipelines and bioinformatics tools, which are critical for extracting meaningful insights from complex miRNA datasets. These tools assist researchers in identifying differentially expressed miRNAs, predicting miRNA targets, and uncovering potential regulatory networks. The integration of bioinformatics resources has made miRNA research more accessible and user-friendly, encouraging researchers to harness the power of miRNA sequencing and assays.
Microarray-Based Techniques
Microarray-based techniques have emerged as a significant driver behind the growth of the Global MiRNA Sequencing and Assay Market. These techniques have played a crucial role in expanding the range of available tools for miRNA analysis, complementing the dominant next-generation sequencing (NGS) technologies. MMchip enables the comprehensive analysis of cross-platform and inter-laboratory data, focusing on the interactions between DNA and proteins. It utilizes two techniques: ChIP-chip (Chromatin Immunoprecipitation followed by array hybridization) and ChIP-seq (Chromatin Immunoprecipitation followed by massively parallel sequencing). Microarrays offer unique advantages that contribute to their popularity in miRNA research and diagnostics, thereby boosting the market. One of the key benefits of microarray-based miRNA profiling is the ability to simultaneously analyze the expression levels of multiple miRNAs in a single experiment. This high-throughput capability allows researchers to examine a broader spectrum of miRNA data, making it particularly suitable for large-scale studies and miRNA signature profiling. As chronic diseases and personalized medicine gain prominence, the need to explore complex miRNA networks and signatures has intensified, and microarrays are well-suited to meet these demands.
Microarray platforms have evolved significantly, offering improved sensitivity and specificity. These enhancements have increased the accuracy and reliability of miRNA data generated through microarray-based techniques, making them a viable option for various research and clinical applications. With the ability to detect subtle changes in miRNA expression, microarrays have become indispensable in identifying miRNA dysregulations associated with diseases. The cost-effectiveness of microarray-based miRNA profiling is another factor contributing to its market growth. While NGS technologies are powerful, they can be relatively costly and resource intensive. Microarrays provide a more budget-friendly alternative, particularly for laboratories with limited financial resources. Researchers and clinicians can achieve comprehensive miRNA profiling without the significant financial burden associated with NGS, making microarrays an accessible and attractive option for a wide range of users.
Key Market Challenges
Data Analysis Complexities
Data analysis complexities represent a significant hindrance to the growth of the Global MiRNA Sequencing and Assay Market. MiRNA sequencing generates vast amounts of data, making it a powerful tool for researchers seeking insights into gene regulation and disease mechanisms. However, the intricate nature of miRNA data, coupled with the need for specialized bioinformatics expertise, poses a considerable challenge for the market. One of the key issues surrounding data analysis in miRNA sequencing is the complexity of the data itself. Unlike other sequencing data, miRNA data is characterized by its relatively short read length, which can make alignment and mapping to reference genomes or miRNA databases more challenging. Additionally, miRNAs can have multiple isoforms and variants, further complicating data analysis.
The identification and quantification of miRNAs require the use of bioinformatics tools that are specifically designed for small RNA sequencing data. Researchers must employ algorithms that can accurately distinguish miRNAs from other small RNAs, such as tRNAs and rRNAs, while also dealing with issues like sequencing errors and variations in miRNA expression levels. miRNA data analysis often involves the detection of differential miRNA expression between experimental conditions, such as healthy and disease states. This process requires statistical approaches to identify significant changes in miRNA expression, adding another layer of complexity. Researchers must account for factors like biological replicates, data normalization, and the multiple testing problem to obtain reliable results.
High Costs
The Global MiRNA Sequencing and Assay Market is a burgeoning sector in genomics and molecular biology, offering profound insights into gene regulation and its implications for various diseases. However, the market faces a substantial challenge in the form of high costs associated with miRNA sequencing and assay technologies. While these techniques hold immense promise, the financial burden they place on research laboratories, clinics, and diagnostic facilities can hinder their widespread adoption. The primary cost factors in miRNA sequencing and assays is the expense of the equipment and technology required for these procedures. Next-generation sequencing (NGS) platforms, which are commonly used for miRNA sequencing, come with a substantial initial investment. The cost of purchasing and maintaining NGS equipment, as well as staying up to date with technological advancements, can strain the budgets of research institutions and clinical facilities.
The reagents and consumables used in miRNA sequencing and assays contribute significantly to the overall cost. These specialized chemicals and kits are often more expensive than those used in conventional molecular biology techniques. The cost of reagents can become a major concern, particularly in high-throughput experiments that require large quantities of materials. Bioinformatics resources and data analysis tools add another layer of expenses. To make sense of the vast amount of data generated by miRNA sequencing, researchers often rely on sophisticated software and computational infrastructure. The licensing, maintenance, and training costs associated with these tools can be substantial.
Key Market Trends
Integration of Bioinformatics Tools
The integration of bioinformatics tools has emerged as a significant driver in boosting the Global MiRNA Sequencing and Assay Market. MiRNA sequencing and assays generate copious amounts of data, making it essential to harness sophisticated computational techniques for data analysis and interpretation. Bioinformatics tools have filled this crucial role, enhancing the efficiency and accessibility of miRNA research and applications. The process begins with Evercode's split-pool combinatorial barcoding, a proprietary technology that assigns cell-specific barcode combinations to molecules. Initially, cells are fixed and permeabilized, effectively transforming them into their own reaction vessels and eliminating the need for capturing individual cells in droplets or microwells. The split-pool barcoding system then assigns an exponentially vast array of barcode combinations to the cells, enabling scalability far beyond other technologies. This approach allows for the parallel processing of up to 1 million cells, even if collected on different days. One of the key advantages of integrating bioinformatics tools into miRNA sequencing and assay workflows is their ability to manage and analyze complex miRNA data. MiRNA sequences are relatively short, and they can have multiple isoforms, making their analysis intricate. Bioinformatics software and algorithms have been specifically designed to handle these intricacies, allowing researchers to accurately identify and quantify miRNAs, distinguish them from other small RNAs, and perform quality control on sequencing data.
Bioinformatics tools play a pivotal role in identifying differentially expressed miRNAs. These tools apply statistical methods to discern significant changes in miRNA expression levels between experimental conditions, such as healthy and disease states. This capability is critical for biomarker discovery and understanding the regulatory roles of miRNAs in various biological processes. The integration of bioinformatics tools is also pivotal in uncovering miRNA-target interactions and regulatory networks. These tools predict potential mRNA targets of miRNAs, shedding light on the downstream effects of miRNA dysregulation. This information is invaluable for understanding disease mechanisms and developing targeted therapies. Bioinformatics resources assist in the integration of miRNA data with other omics data, such as mRNA and proteomic profiles. The combined analysis of multiple data types is essential for elucidating complex regulatory networks and molecular interactions, particularly in personalized medicine and disease research.
Segmental Insights
Technology Insights
Based on Technology, Sequencing by Synthesis have emerged as the fastest growing segment in the Global MiRNA Sequencing and Assay Market in 2024. Sequencing by Synthesis has a well-established and proven track record in the genomics field. It has been widely adopted for various sequencing applications, including miRNA profiling. Researchers and clinicians often prefer technologies with a history of success and reliability, which Sequencing by Synthesis offers. SBS platforms are renowned for their high-throughput capabilities. They can process a large number of samples simultaneously, making them well-suited for large-scale miRNA profiling studies. The ability to handle multiple samples efficiently and cost-effectively aligns with the demands of miRNA research, where extensive datasets are often required to uncover meaningful insights.
Application Insights
Based on Application, Cancer have emerged as the dominant segment in the Global MiRNA Sequencing and Assay Market in 2024. Cancer is a leading cause of morbidity and mortality worldwide, contributing to a substantial global disease burden. The need for effective cancer diagnosis, prognosis, and treatment strategies is paramount, which has driven extensive research into miRNA profiling. MiRNAs have been identified as critical regulators of gene expression in cancer, making them attractive targets for understanding cancer biology and developing novel therapies. MiRNA profiling offers significant diagnostic and prognostic value in cancer. Specific miRNA signatures or dysregulations have been associated with different cancer types, stages, and patient outcomes. By analyzing miRNA expression patterns, clinicians can identify cancer subtypes, predict disease progression, and assess patient prognosis. This diagnostic potential has led to the integration of miRNA profiling into clinical oncology.
Regional Insights
Based on Region, North America have emerged as the dominant region in the Global MiRNA Sequencing and Assay Market in 2024, holding the largest market share. The United States and Canada, in particular, have highly advanced healthcare systems with a strong emphasis on research and innovation. The integration of miRNA profiling into clinical practice, precision medicine initiatives, and the development of targeted therapies has significantly contributed to the adoption of miRNA sequencing and assays. North America hosts a significant portion of the global pharmaceutical and biotechnology industry. These companies play a pivotal role in drug discovery and development, where miRNA profiling is extensively used for target identification, companion diagnostics, and biomarker discovery. The close collaboration between academia and the industry further fuels the demand for miRNA technologies.
In this report, the Global MiRNA Sequencing and Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global MiRNA Sequencing and Assay Market.
Global MiRNA Sequencing and Assay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: